Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
Status:
Completed
Trial end date:
2020-06-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel
that can be applied to the skin (called transdermal application) twice a day for the
treatment of behavioral symptoms of Fragile X Syndrome (FXS). Eligible participants will then
participate in up to a 14 week treatment period, where all participants will receive placebo
or active study drug. Patients ages 3 to < 18 years, will be eligible to participate.